Pharma Journalist -

Novartis announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA (onasemnogene…
Read More...

UCB announced that it has received an Import Drug License (IDL) from the National Drug Administration of China (CNDA), creating a pathway to make VIMPAT (lacosamide) available to treat…
Read More...

SMi’s Adaptive Designs in Clinical Trials to return in London next Spring SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and…
Read More...

IQVIA announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’…
Read More...

Autolus Therapeutics plc announced that the first patient has been dosed in its Phase 1/2 LibrA T1 clinical trial of AUTO4, a developmental therapy for the treatment of relapsed or…
Read More...

The 2nd Annual Pharmaceutical Microbiology East Coast conference is returning to the Battery Wharf Hotel, Boston, USA on April 10th and 11th, 2019 The two-day conference will be…
Read More...

Merck announced that the European Commission has approved DELSTRIGO and PIFELTRO for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of…
Read More...

AbCellera announced its collaboration with Autolus Therapeutics plc (Autolus), a clinical stage biopharmaceutical company developing next-generation programmed T cell therapies. Under…
Read More...

Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have announced that they have signed a collaboration agreement to jointly evaluate the feasibility of 225Ac-labeled…
Read More...

Coeptis Pharmaceuticals announced that it has entered into a binding agreement to acquire all outstanding shares of Elto Pharma, Inc. Elto Phama is developing eltoprazine, a…
Read More...